More importantly, our first establishment of CRISPR/Cas9-based gene therapy against the above-identified GBM invasion regulator, IGFBP5, showed a much preferable outcome on tumor growth as well as mouse life expectancy, comparing to the well-known siRNA-based therapies targeting the conventional GBM targets (i.e., PLK137 or STAT368). This evidence concerns the gene IGFBP5 and neoplasm.